Opticyte

Opticyte

Open  for investment

About this raise

Opticyte, with a valuation of $12.08 million, is raising funds on StartEngine. The company has developed a breakthrough device for accurate oxygen measurements. Opticyte’s VitalO2 device measures oxygen accurately for all skin tones and enables early detection of sepsis to close critical healthcare gaps. The AI-enabled device combines advanced pulse oximetry and cellular oxygenation for early detection of sepsis and early signs of organ failure and enables quicker intervention and better patient outcomes. Lorilee Siu Lin Arakaki and Kenneth Schenkman founded Opticyte in May 2016. The current crowdfunding campaign has a minimum and maximum target of $123,999.81. The campaign proceeds will be used for design, pivotal study for early recognition of sepsis, completion of algorithm development, and working capital.

Expand

Investment Overview

Committed this round: $214,933

Deal Terms

Total Commitments

Platform
StartEngine
Start Date
11/01/2024
Close Date
06/30/2025
Min. Goal
$124,000
Max Goal
$1,235,000
Min. Investment

$301

Security Type

Equity - Common

Company Stage

Early Stage

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$0.33

Pre-Money Valuation

$12,078,000

Company & Team

Company

Year Founded
2016
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Location
Seattle, Washington
Business Type
Growth
Company Website
Visit Website

Team

Employees
2
Prior Founder Exits?
No
Founder Name
Lori Arakaki
Title
CEO
Founder Name
Kenneth Schenkman
Title
CMO

Financials

 Revenue
$0
as of FY2024
 Monthly Burn
$15,000
as of Sep '24
 Runway
8 months
as of Sep '24

Summary Profit and Loss Statement

FY 2024 FY 2023

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-694,846

$-587,265

Summary Balance Sheet

FY 2024 FY 2023

Cash

$133,063

$193,310

Accounts Receivable

$0

$0

Total Assets

$133,063

$196,566

Short-Term Debt

$1,651,625

$2,257,331

Long-Term Debt

$1,721,250

$495,000

Total Liabilities

$3,372,875

$2,752,331

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$3,000,000
VC Backed?
Yes
Close Date Platform Valuation Total Raised Security Type Status Reg Type
06/30/2025 StartEngine $12,078,000 $214,933 Equity - Common Active RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Opticyte on StartEngine 2024
Platform: StartEngine
Security Type: Equity - Common
Valuation: $12,078,000
Price per Share: $0.33

Follow company

Follow Opticyte on StartEngine 2024

Buy Opticyte's Deal Report

Opticyte Deal Report

Get Kingscrowd's comprehensive report on Opticyte including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Opticyte is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Opticyte deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge